Dental Innovation Alliance Backs Waitly’s AI Scheduling Platform

Dental Innovation Alliance (DIA) has made a strategic investment in Waitly, an AI-native scheduling company that identifies unused dental capacity and books patients without requiring staff to work a waitlist manually. The parties announced the investment on November 12, 2026. They did not disclose the size or terms of DIA's investment.

Waitly is based in Raleigh, North Carolina, and says it is already live with multi-location healthcare groups ranging from 11 to nearly 200 locations, including general dentistry, pediatric dentistry and orthodontics. The investment gives the company more than capital: DIA's dental-operator and DSO network is closely aligned with Waitly's target buyer.

What the platform does

Waitly connects bidirectionally with a practice-management or EHR system and monitors provider calendars for openings. When capacity appears, it evaluates patients from sources such as waitlists, canceled appointments, hygiene recall, accepted-but-unscheduled treatment and lapsed care.

The company says its ranking uses factors including clinical urgency, provider preference, likelihood to show and economic value. It then contacts candidates sequentially through AI-driven SMS or voice interactions and writes confirmed appointments back to the source system.

That approach is different from a conventional booking portal or inbound AI receptionist. Waitly is designed to initiate work from demand already stored in the practice system rather than wait for a patient to call or visit a website.

The early operating claims are material—but company-reported

DIA's announcement includes a detailed customer example. A 45-location DSO reportedly launched Waitly seven days after signing and initially used one workflow across seven clinics. Over ten weeks, the group recovered approximately $84,900 in scheduled production and saved an estimated 837 staff hours.

After expanding across the organization, the DSO reportedly attributed more than $320,000 in additional scheduled production in September to Waitly, including hygiene, crown and Invisalign appointments.

Those figures are more useful than a generic claim that AI improves scheduling, but they remain vendor- and investor-reported. The announcement does not identify the DSO, publish a baseline cancellation rate, disclose the number of booked appointments or explain how staff hours and incremental production were calculated. Production is also not the same as collected revenue or contribution margin.

Why the investment matters

Empty chairs are a direct margin problem for dental groups because most location-level labor, occupancy and equipment costs remain fixed when an appointment cancels. Recovering capacity can therefore produce more operating leverage than simply reducing the time required for an administrative task.

The development fits the shift described in Avized's analysis of dental's next value-creation cycle: technology is becoming more credible when it can demonstrate measurable practice-level outcomes rather than only feature adoption.

It also shows the scheduling market moving from reminders and inbound booking toward autonomous execution. Avized's analysis of native agentic PMS workflows describes the same broader transition: software is increasingly expected to identify work, take action and update the system of record with controlled human oversight.

For DSOs, the architecture matters as much as the algorithm. A scheduling agent must work across different practice-management systems, provider templates, appointment types and local operating rules without becoming another disconnected workflow. Avized's 10–100-location DSO technology-stack guide explains why data access, integration governance and consistent KPI definitions become strategic as groups scale.

Funding context

DIA did not disclose the amount of its investment. A separate Waitly Form D filed with the SEC on August 31 reports that the company sold $2.5 million of SAFE securities to six investors, with the first sale occurring August 24. The filing does not name those investors or establish how much, if any, of that offering came from DIA. The $2.5 million should therefore be treated as company funding context, not as the disclosed size of DIA's investment.

What to watch next

Verified economics. Buyers should ask for booked-appointment counts, show rates, completed production, collections and contribution margin—not only scheduled production.

Incrementality. The most important question is how many patients would not have scheduled without the platform, rather than how many bookings passed through it.

Patient experience. Sequential outreach may be less disruptive than mass texting, but operators should measure opt-outs, complaints, response quality and whether clinical urgency is represented accurately.

Integration depth. Waitly says implementation on an already integrated system can take roughly one week. DSOs should verify write-back controls, audit trails, multi-PMS support and exception handling before extrapolating that timeline.

Independent customer evidence. The reported 45-location deployment is promising. A named case study with methodology and sustained results would materially strengthen the commercial proof.

The investment is significant because it pairs an automation product with investors who can open doors to large dental groups. The next test is whether Waitly can demonstrate that recovered schedule capacity converts into durable collections and margin across a diverse DSO footprint.

Primary sources

• Dental Innovation Alliance — strategic investment announcement, November 12, 2026
• Waitly — product overview
• Waitly — SEC Form D filed August 31, 2026

Investment scope, product capabilities and operating results are attributed to DIA and Waitly. SEC funding figures are reported as filed by the company. Avized's market implications and evaluation framework are independent editorial analysis.